NASDAQ:REGN - Regeneron Stock Price, Price Target & More

$314.25 -1.58 (-0.50 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$314.25
Today's Range$311.34 - $318.19
52-Week Range$311.34 - $543.55
Volume683,001 shs
Average Volume928,229 shs
Market Capitalization$34.61 billion
P/E Ratio23.43
Dividend YieldN/A

About Regeneron (NASDAQ:REGN)

Regeneron logoRegeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.11%
Current Ratio3.82%
Quick Ratio3.18%


Trailing P/E Ratio23.43
Forward P/E Ratio16.37
P/E Growth1.04

Sales & Book Value

Annual Sales$5.87 billion
Price / Sales5.76
Cash Flow$15.5109 per share
Price / Cash20.26
Book Value$57.09 per share
Price / Book5.50


EPS (Most Recent Fiscal Year)$13.41
Net Income$1.20 billion
Net Margins20.41%
Return on Equity28.48%
Return on Assets19.26%


Outstanding Shares107,700,000

How to Become a New Pot Stock Millionaire

Regeneron (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron's stock symbol?

Regeneron trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron's earnings last quarter?

Regeneron (NASDAQ:REGN) issued its quarterly earnings data on Thursday, February, 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping analysts' consensus estimates of $4.18 by $1.05. The biopharmaceutical company earned $1.58 billion during the quarter, compared to the consensus estimate of $1.50 billion. Regeneron had a net margin of 20.41% and a return on equity of 28.48%. Regeneron's revenue for the quarter was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.04 earnings per share. View Regeneron's Earnings History.

When is Regeneron's next earnings date?

Regeneron is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Regeneron.

What price target have analysts set for REGN?

25 brokerages have issued twelve-month price targets for Regeneron's shares. Their predictions range from $356.00 to $593.00. On average, they anticipate Regeneron's share price to reach $454.9167 in the next twelve months. View Analyst Ratings for Regeneron.

What are Wall Street analysts saying about Regeneron stock?

Here are some recent quotes from research analysts about Regeneron stock:
  • 1. According to Zacks Investment Research, "Regeneron’s top-line continues to be driven by strong Eylea sales. The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales in 2018. The action date set by the FDA is Aug 11, 2018. The approval of new drugs like Kevzara and Dupixent provides a significant boost. Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. Kevzara is also expected to pick up further. A potential approval of PD-1 antibody cemiplimab, in advanced cutaneous squamous cell carcinoma will further boost prospects. However, shares of the company have underperformed the industry in the last 12 months. Sales of Praluent have failed to impress to date." (4/11/2018)
  • 2. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018)

Who are some of Regeneron's key competitors?

Who are Regeneron's key executives?

Regeneron's management team includes the folowing people:
  • Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 65)
  • Dr. George D. Yancopoulos, Pres, Chief Scientific Officer & Director (Age 58)
  • Mr. Robert E. Landry Jr., Sr. VP of Fin. & CFO (Age 54)
  • Dr. Neil Stahl Ph.D., Exec. VP of R&D (Age 61)
  • Mr. Robert J. Terifay, Exec. VP of Commercial(Leave of Absence) (Age 58)

Has Regeneron been receiving favorable news coverage?

News coverage about REGN stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Regeneron earned a news sentiment score of 0.09 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 44.46 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Regeneron?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron's stock price today?

One share of REGN stock can currently be purchased for approximately $314.25.

How big of a company is Regeneron?

Regeneron has a market capitalization of $34.61 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron employs 6,200 workers across the globe.

How can I contact Regeneron?

Regeneron's mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

MarketBeat Community Rating for Regeneron (REGN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  1,035 (Vote Outperform)
Underperform Votes:  836 (Vote Underperform)
Total Votes:  1,871
MarketBeat's community ratings are surveys of what our community members think about Regeneron and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Regeneron (NASDAQ:REGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
25 Wall Street analysts have issued ratings and price targets for Regeneron in the last 12 months. Their average twelve-month price target is $454.9167, suggesting that the stock has a possible upside of 44.76%. The high price target for REGN is $593.00 and the low price target for REGN is $356.00. There are currently 1 sell rating, 16 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.282.362.382.39
Ratings Breakdown: 1 Sell Rating(s)
16 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
14 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
14 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
13 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $454.9167$455.75$472.50$492.56
Price Target Upside: 44.76% upside32.27% upside25.50% upside13.82% upside

Regeneron (NASDAQ:REGN) Consensus Price Target History

Price Target History for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ:REGN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Credit Suisse GroupLower Price TargetBuy$440.00 -> $420.00LowView Rating Details
4/9/2018Raymond JamesReiterated RatingOutperform -> Market PerformLowView Rating Details
4/9/2018UBSDowngradeOutperform -> Market PerformLowView Rating Details
3/13/2018BTIG ResearchReiterated RatingHoldMediumView Rating Details
3/13/2018Deutsche BankSet Price TargetHold$367.00MediumView Rating Details
2/21/2018Canaccord GenuityDowngradeBuy -> Hold$522.00 -> $356.00MediumView Rating Details
2/9/2018SunTrust BanksSet Price TargetHold$430.00LowView Rating Details
2/9/2018Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$401.00 -> $415.00HighView Rating Details
2/9/2018Leerink SwannLower Price TargetOutperform -> Outperform$568.00 -> $502.00HighView Rating Details
2/9/2018Robert W. BairdUpgradeNeutral -> OutperformHighView Rating Details
2/9/2018GuggenheimSet Price TargetBuy$530.00HighView Rating Details
2/8/2018Jefferies GroupReiterated RatingNeutral -> Hold$380.00HighView Rating Details
2/8/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$398.00 -> $444.00LowView Rating Details
2/7/2018CowenReiterated RatingHold$450.00HighView Rating Details
1/24/2018JPMorgan ChaseBoost Price TargetNeutral -> Neutral$455.00 -> $457.00LowView Rating Details
1/9/2018CitigroupReiterated RatingNeutral -> Neutral$380.00 -> $388.00HighView Rating Details
12/28/2017ArgusLower Price TargetPositive -> Buy$540.00 -> $470.00LowView Rating Details
12/14/2017Royal Bank of CanadaReiterated RatingHold$430.00LowView Rating Details
11/16/2017Evercore ISILower Price TargetOutperform$605.00 -> $445.00N/AView Rating Details
11/13/2017Piper JaffrayReiterated RatingBuy$540.00N/AView Rating Details
10/20/2017BarclaysDowngradeEqual Weight -> Underweight$450.00 -> $395.00N/AView Rating Details
9/27/2017OppenheimerReiterated RatingHoldLowView Rating Details
8/9/2017Goldman SachsReiterated RatingNeutral$469.00 -> $472.00LowView Rating Details
7/21/2017Bank of AmericaReiterated RatingBuy$589.00 -> $593.00LowView Rating Details
6/26/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$410.00 -> $480.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
1/10/2017Wells FargoReiterated RatingMarket PerformN/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
(Data available from 4/21/2016 forward)


Regeneron (NASDAQ:REGN) Earnings History and Estimates Chart

Earnings by Quarter for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ:REGN) Earnings Estimates

Current Year EPS Consensus Estimate: $19.2 EPS
Next Year EPS Consensus Estimate: $20.07 EPS

Regeneron (NASDAQ REGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$4.17N/AView Earnings Details
2/8/2018Q4 2017$4.18$5.23$1.5048 billion$1.5820 billionViewN/AView Earnings Details
11/8/2017Q3 2017$3.83$3.99$1.4498 billion$1.5010 billionViewN/AView Earnings Details
8/3/2017Q2 2017$2.67$4.17$1.3572 billion$1.47 billionViewListenView Earnings Details
5/4/2017Q1 2017$2.50$2.92$1.2992 billion$1.3190 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.75)($0.68)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.38)($0.49)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.32)($0.17)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.34)($0.41)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.38)($0.31)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.49)($0.38)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.34)($0.46)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.23)($0.01)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.28)($0.19)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.29)($0.22)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.30)($0.40)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.32)($0.27)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.35)($0.22)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.34)($0.15)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.46)($0.19)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Regeneron (NASDAQ:REGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Regeneron (NASDAQ REGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.80%
Institutional Ownership Percentage: 66.40%
Insider Trading History for Regeneron (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ REGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2018Joseph L GoldsteinDirectorSell2,000$350.02$700,040.0014,000View SEC Filing  
3/14/2018Joseph L GoldsteinDirectorSell2,000$340.00$680,000.0014,000View SEC Filing  
2/9/2018Joseph L GoldsteinDirectorSell1,000$325.60$325,600.00View SEC Filing  
10/5/2017Michael S BrownDirectorSell1,500$475.00$712,500.00View SEC Filing  
9/29/2017Charles A BakerDirectorSell2,000$450.00$900,000.0011,000View SEC Filing  
9/6/2017Robert E LandrySVPSell663$498.60$330,571.8010,099View SEC Filing  
9/5/2017Robert E LandryCFOSell189$501.06$94,700.3410,099View SEC Filing  
8/31/2017Robert E LandrySVPSell427$493.43$210,694.619,099View SEC Filing  
8/25/2017SanofiMajor ShareholderBuy72,378$481.36$34,839,874.08View SEC Filing  
8/24/2017SanofiMajor ShareholderBuy166,415$480.93$80,033,965.95View SEC Filing  
8/23/2017Robert E LandrySVPSell468$476.45$222,978.609,099View SEC Filing  
8/22/2017P Roy VagelosChairmanSell56,213$474.48$26,671,944.24363,638View SEC Filing  
8/18/2017P Roy VagelosChairmanSell15,191$470.15$7,142,048.65329,543View SEC Filing  
8/17/2017P Roy VagelosChairmanSell1,305$470.00$613,350.00329,543View SEC Filing  
8/16/2017P Roy VagelosChairmanSell10,986$470.17$5,165,287.62329,543View SEC Filing  
8/8/2017Robert E LandrySVPSell526$472.19$248,371.949,099View SEC Filing  
6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.989,193View SEC Filing  
6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.3043,950View SEC Filing  
6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.003,000View SEC Filing  
6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.9372,043View SEC Filing  
6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.1544,245View SEC Filing  
6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.0014,000View SEC Filing  
6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.8828,477View SEC Filing  
6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50View SEC Filing  
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30414,156View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.003,000View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.001,000View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.0012,000View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.0036,500View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.0015,125View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.0015,125View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.0040,500View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.0111,381View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.0013,000View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.0016,000View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.326,866View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44500,000View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00332,880View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.4522,029View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98351,851View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28543,348View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.009,000View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.1715,441View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.009,000View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.0014,662View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.0014,662View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.0563,102View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.5863,102View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.001,000View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.1615,600View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.2020,029View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.8424,391View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.711,068,343View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.002,000View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.5069,960View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.3625,447View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.9320,742View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00112,772View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.003,000View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.8342,087View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.1665,759View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.0910,736View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.0016,644View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.004,000View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Regeneron (NASDAQ REGN) News Headlines

Analysts’ Recommendations for Exelixis in April 2018Analysts’ Recommendations for Exelixis in April 2018 - April 19 at 10:28 AM
BidaskClub Lowers Regeneron (REGN) to SellBidaskClub Lowers Regeneron (REGN) to Sell - April 18 at 9:51 AM
Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest? - April 17 at 3:55 PM
Regeneron (REGN) Price Target Cut to $420.00Regeneron (REGN) Price Target Cut to $420.00 - April 17 at 1:29 PM
Regeneron (REGN) Rating Lowered to Underperform at Robert W. BairdRegeneron (REGN) Rating Lowered to Underperform at Robert W. Baird - April 14 at 4:13 PM
Regeneron (REGN) Given "Overweight" Rating at Piper JaffrayRegeneron (REGN) Given "Overweight" Rating at Piper Jaffray - April 14 at 3:07 PM
Regeneron (REGN) Stock Rating Reaffirmed by JPMorgan ChaseRegeneron (REGN) Stock Rating Reaffirmed by JPMorgan Chase - April 13 at 5:29 PM
BMO Capital Markets Reiterates $491.00 Price Target for Regeneron (REGN)BMO Capital Markets Reiterates $491.00 Price Target for Regeneron (REGN) - April 13 at 10:53 AM
Oakmark fund manager talks his Q1 buysOakmark fund manager talks his Q1 buys - April 12 at 3:51 PM
3 Biotech Stocks Analysts Have Been Too Bullish On3 Biotech Stocks Analysts Have Been Too Bullish On - April 12 at 3:51 PM
Exploring the Growth of Regeneron’s PraluentExploring the Growth of Regeneron’s Praluent - April 12 at 3:51 PM
Free Research Reports on These Biotech Stocks -- Regeneron Pharma, Sangamo Therapeutics, Seattle Genetics, and ...Free Research Reports on These Biotech Stocks -- Regeneron Pharma, Sangamo Therapeutics, Seattle Genetics, and ... - April 12 at 11:20 AM
Regeneron (REGN) Receives "Outperform" Rating from Leerink SwannRegeneron (REGN) Receives "Outperform" Rating from Leerink Swann - April 11 at 11:52 PM
Regeneron (REGN) Earns "Neutral" Rating from Goldman SachsRegeneron (REGN) Earns "Neutral" Rating from Goldman Sachs - April 11 at 11:52 PM
Regeneron (REGN) Given Hold Rating at JPMorgan ChaseRegeneron (REGN) Given Hold Rating at JPMorgan Chase - April 11 at 11:52 PM
Regeneron (REGN) Upgraded to Strong-Buy by Zacks Investment ResearchRegeneron (REGN) Upgraded to Strong-Buy by Zacks Investment Research - April 11 at 6:44 PM
Vertex Is Worth More Than You ThinkVertex Is Worth More Than You Think - April 11 at 3:46 PM
Zacks Investment Research Lowers Regeneron (REGN) to HoldZacks Investment Research Lowers Regeneron (REGN) to Hold - April 11 at 1:48 PM
Zacks: Analysts Anticipate Regeneron (REGN) Will Post Quarterly Sales of $1.54 BillionZacks: Analysts Anticipate Regeneron (REGN) Will Post Quarterly Sales of $1.54 Billion - April 10 at 3:13 AM
Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018 - April 9 at 10:42 AM
Regeneron (REGN) Rating Reiterated by Raymond James FinancialRegeneron (REGN) Rating Reiterated by Raymond James Financial - April 9 at 8:51 AM
Regeneron (REGN) Cut to Market Perform at UBSRegeneron (REGN) Cut to Market Perform at UBS - April 9 at 8:12 AM
Regeneron (REGN) Expected to Post Earnings of $4.49 Per ShareRegeneron (REGN) Expected to Post Earnings of $4.49 Per Share - April 8 at 3:10 PM
JPMorgan Chase Reiterates "Hold" Rating for Regeneron (REGN)JPMorgan Chase Reiterates "Hold" Rating for Regeneron (REGN) - April 6 at 9:50 PM
Wired News – EMA to Review Regeneron’s Marketing Authorization Application for CemiplimabWired News – EMA to Review Regeneron’s Marketing Authorization Application for Cemiplimab - April 5 at 8:09 AM
Regeneron Pharmaceuticals Inc (REGN) Given Consensus Rating of "Hold" by BrokeragesRegeneron Pharmaceuticals Inc (REGN) Given Consensus Rating of "Hold" by Brokerages - April 4 at 5:34 PM
Regeneron (REGN) & Sanofi (SNY) Report EMA to Review DUPIXENT (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe AsthmaRegeneron (REGN) & Sanofi (SNY) Report EMA to Review DUPIXENT (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma - April 3 at 3:52 PM
EMA Accepts Regeneron/Sanofis application for DupixentEMA Accepts Regeneron/Sanofi's application for Dupixent - April 3 at 10:42 AM
EMA accepts marketing application for Dupixent for asthmaEMA accepts marketing application for Dupixent for asthma - April 3 at 10:42 AM
Amgen's (AMGN) Xgeva Gets EU Approval for Expanded LabelAmgen's (AMGN) Xgeva Gets EU Approval for Expanded Label - April 3 at 10:42 AM
Regeneron Pharmaceuticals’ Dupixent, Kevzara, and ZaltrapRegeneron Pharmaceuticals’ Dupixent, Kevzara, and Zaltrap - April 2 at 10:53 AM
Regeneron Pharmaceuticals (REGN) Given "Buy" Rating at CitigroupRegeneron Pharmaceuticals (REGN) Given "Buy" Rating at Citigroup - March 31 at 8:16 PM
Regeneron Pharmaceuticals (REGN) "Sector Perform" Rating Reiterated at Royal Bank of CanadaRegeneron Pharmaceuticals' (REGN) "Sector Perform" Rating Reiterated at Royal Bank of Canada - March 31 at 6:06 PM
A Post-4Q17 Update on Praluent’s PerformanceA Post-4Q17 Update on Praluent’s Performance - March 30 at 3:44 PM
How Regeneron Pharmaceuticals’ Eylea Performed in 4Q17 and 2017How Regeneron Pharmaceuticals’ Eylea Performed in 4Q17 and 2017 - March 30 at 10:24 AM
Citigroup Reiterates "Neutral" Rating for Regeneron Pharmaceuticals (REGN)Citigroup Reiterates "Neutral" Rating for Regeneron Pharmaceuticals (REGN) - March 29 at 11:52 PM
BidaskClub Upgrades Regeneron Pharmaceuticals (REGN) to "Hold"BidaskClub Upgrades Regeneron Pharmaceuticals (REGN) to "Hold" - March 29 at 11:28 AM
BioMarin's MAA for Phenylketonuria Candidate Gains EU NodBioMarin's MAA for Phenylketonuria Candidate Gains EU Nod - March 29 at 10:52 AM
Regeneron CEO: There are structural issues around drug pr...Regeneron CEO: There are structural issues around drug pr... - March 28 at 3:41 PM
Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) A Sell At Its Current PE Ratio?Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) A Sell At Its Current PE Ratio? - March 27 at 3:52 PM
$1.54 Billion in Sales Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter$1.54 Billion in Sales Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter - March 24 at 4:49 AM
Alnylam and Regeneron team up in NASH - Seeking AlphaAlnylam and Regeneron team up in NASH - Seeking Alpha - March 23 at 6:25 PM
Regeneron (REGN) Genetics Center Publication in NEJM Identifies New Genetic Variant Providing Protection from Chronic Liver DiseaseRegeneron (REGN) Genetics Center Publication in NEJM Identifies New Genetic Variant Providing Protection from Chronic Liver Disease - March 23 at 9:52 AM
Regeneron Collaborates With Alnylam to Develop NASH TreatmentRegeneron Collaborates With Alnylam to Develop NASH Treatment - March 22 at 3:58 PM
Powerhouse Duo Takes On Gilead, Allergan In Liver Disease, But Stocks DipPowerhouse Duo Takes On Gilead, Allergan In Liver Disease, But Stocks Dip - March 22 at 3:58 PM
Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA ApprovalRoche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval - March 22 at 3:58 PM
Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead? - March 22 at 3:58 PM
FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY ... - NasdaqFENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY ... - Nasdaq - March 22 at 10:12 AM
Regeneron (REGN) Genetics Center Publication in NEJM Identifies ... - StreetInsider.comRegeneron (REGN) Genetics Center Publication in NEJM Identifies ... - - March 22 at 10:12 AM
GlaxoSmithKline Initiates Phase III Combo Study on BenlystaGlaxoSmithKline Initiates Phase III Combo Study on Benlysta - March 21 at 3:57 PM

SEC Filings

Regeneron (NASDAQ:REGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Regeneron (NASDAQ:REGN) Income Statement, Balance Sheet and Cash Flow Statement


Regeneron (NASDAQ REGN) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.